JP2023531869A5 - - Google Patents
Info
- Publication number
- JP2023531869A5 JP2023531869A5 JP2022571216A JP2022571216A JP2023531869A5 JP 2023531869 A5 JP2023531869 A5 JP 2023531869A5 JP 2022571216 A JP2022571216 A JP 2022571216A JP 2022571216 A JP2022571216 A JP 2022571216A JP 2023531869 A5 JP2023531869 A5 JP 2023531869A5
- Authority
- JP
- Japan
- Prior art keywords
- tetramethyl
- oxo
- ions
- oxazaphosfinan
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR2005138A FR3110393B1 (fr) | 2020-05-20 | 2020-05-20 | Compose et composition pour induire une neuroprotection |
| FR2005138 | 2020-05-20 | ||
| PCT/FR2021/050929 WO2021234324A1 (fr) | 2020-05-20 | 2021-05-20 | Compose et composition pour induire une neuroprotection |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023531869A JP2023531869A (ja) | 2023-07-26 |
| JP2023531869A5 true JP2023531869A5 (cg-RX-API-DMAC7.html) | 2024-05-27 |
Family
ID=73013493
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022571216A Pending JP2023531869A (ja) | 2020-05-20 | 2021-05-20 | 神経保護を誘導するための化合物及び組成物 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US12611387B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4142703B8 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023531869A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230013116A (cg-RX-API-DMAC7.html) |
| CN (1) | CN116981449A (cg-RX-API-DMAC7.html) |
| CA (1) | CA3178633A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2970378T3 (cg-RX-API-DMAC7.html) |
| FR (1) | FR3110393B1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021234324A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR3149773B1 (fr) | 2023-06-19 | 2026-04-17 | Rest Therapeutics | Nouvelles combinaisons synergiques a base de fenm |
| FR3163834A1 (fr) | 2024-06-26 | 2026-01-02 | Rest Therapeutics | Derives de fluoroethylnormemantine |
| WO2026003229A1 (fr) | 2024-06-26 | 2026-01-02 | Rest Therapeutics | Derives de fluoroethylnormemantine pour leur utilisation en tant que medicament |
| FR3163835B1 (fr) | 2024-06-26 | 2026-06-26 | Rest Therapeutics | Derives de fluoroethylnormemantine |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100339070C (zh) * | 2002-10-24 | 2007-09-26 | 莫茨药物股份两合公司 | 包含1-氨基环己烷衍生物类和乙酰胆碱酯酶抑制剂类的药物组合物 |
| BRPI0516112A (pt) * | 2004-10-15 | 2008-08-26 | Janssen Pharmaceutica Nv | métodos para neuroproteção |
| US20090118376A1 (en) * | 2007-11-02 | 2009-05-07 | Ru-Band Lu | Memantine Protects Inflammation-Related Degeneration of Dopamine Neurons Through Inhibition of Over-Activated Microglia and Release of Neurotrophic Factors from Astroglia |
| FR2935611B1 (fr) | 2008-09-10 | 2010-10-15 | Commissariat Energie Atomique | Utilisation d'agents anti-connexines pour moduler l'effet therapeutique de molecules psychotropes |
| US20120115943A1 (en) * | 2008-10-01 | 2012-05-10 | National Taiwan University | Composition and method for neuroprotection against excitotoxic injury |
| EP2586436A1 (en) * | 2011-10-31 | 2013-05-01 | Commissariat à l'Énergie Atomique et aux Énergies Alternatives | Use of anti-connexin agents for enhancing the therapeutic effect of acetylcholinesterase inhibitor |
| FR3006193B1 (fr) * | 2013-05-29 | 2015-06-19 | Holis Technologies | Nouveaux composes chimiques derives de la memantine et susceptibles de se fixer sur les recepteurs de n-methyl-d-aspartate (nmda) |
| FR3050732B1 (fr) | 2016-05-02 | 2019-06-28 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Nouveaux derives de phosphinolactones et leurs utilisations pharmaceutiques |
| FR3075038B1 (fr) | 2017-12-15 | 2020-03-06 | Melchior Material And Life Science France | Utilisation de la fluoroethylnormemantine pour la prevention de l'apparition et le traitement de l'anxiete |
| WO2020232246A1 (en) * | 2019-05-15 | 2020-11-19 | The Trustees Of Columbia University In The City Of New York | Compositions and methods against stress-induced affective disorders and their associated symptoms |
-
2020
- 2020-05-20 FR FR2005138A patent/FR3110393B1/fr active Active
-
2021
- 2021-05-20 ES ES21734182T patent/ES2970378T3/es active Active
- 2021-05-20 US US17/924,420 patent/US12611387B2/en active Active
- 2021-05-20 CN CN202180060125.1A patent/CN116981449A/zh active Pending
- 2021-05-20 KR KR1020227044712A patent/KR20230013116A/ko active Pending
- 2021-05-20 EP EP21734182.5A patent/EP4142703B8/fr active Active
- 2021-05-20 CA CA3178633A patent/CA3178633A1/fr active Pending
- 2021-05-20 WO PCT/FR2021/050929 patent/WO2021234324A1/fr not_active Ceased
- 2021-05-20 JP JP2022571216A patent/JP2023531869A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2368604C2 (ru) | Ингибиторы фосфодиэстеразы 4, включающие n-замещенные аналоги анилина и дифениламина | |
| EP2813498B1 (en) | Compounds for Alzheimer's disease | |
| JP2006504656A5 (cg-RX-API-DMAC7.html) | ||
| US9034871B2 (en) | Compounds for Alzheimer's disease | |
| US20120225845A1 (en) | Compounds for diseases and disorders | |
| JP2005506308A5 (cg-RX-API-DMAC7.html) | ||
| JP2025004090A (ja) | 統合失調症を治療するための2-((1-(2(4-フルオロフェニル)-2-オキソエチル)ピペリジン-4-イル)メチル)イソインドリン-1-オン | |
| US20080188524A1 (en) | Methods of treating pain | |
| AU2007214128B2 (en) | Use of KCNQ-openers for treating or reducing the symptoms of schizophrenia | |
| EP1641461B1 (fr) | Association d'un antagoniste ou agoniste inverse du recepteur h3 de l'histamine avec un anti-psychotique ou un antidepresseur et son utilisation pour preparer un medicament prevenant des effets indesirables de medicaments psychotropes | |
| JP2022513030A (ja) | ヒストン脱アセチル化酵素6阻害剤を含む薬学的組成物 | |
| JP2022137234A (ja) | 神経変性疾患の予防及び/又は治療剤 | |
| AU2008222890B2 (en) | Methods for treating cognitive disorders using 3-aryl-3-hydroxy-2-amino-propionic acid amides, 3-heteroaryl-3-hydroxy-2-amino-propionic acid amides and related compounds | |
| JP7309824B2 (ja) | 不安障害を治療するための(2S)-1-[4-(3,4-ジクロロフェニル)ピペリジン-1-イル]-3-[2-(5-メチル-1,3,4-オキサジアゾール-2-イル)ベンゾ[b]フラン-4-イルオキシ]プロパン-2-オールまたはその代謝産物 | |
| WO2013161993A1 (ja) | トランス-2-デセン酸誘導体及びこれを含有する医薬 | |
| KR930006009A (ko) | 4-[4-[4-(4-히드록시페닐)-1-피페라지닐]페닐]-5-메틸-3h-1,2,4-트리아졸-3-온 유도체 | |
| JP2005501834A5 (cg-RX-API-DMAC7.html) | ||
| US7470708B2 (en) | Acidic quinoline derivatives and their use for the prevention and/or treatment of hyperglycaemia-related pathologies | |
| JP6025886B2 (ja) | 慢性疼痛治療剤 | |
| KR101503782B1 (ko) | 신경 세포사 억제제 | |
| TW201208683A (en) | Flufenoxine derivatives for the treatment and prevention of amiloyd pathologies | |
| JPH11335286A (ja) | ドーパミン拮抗薬の効果増強剤 | |
| TH2101008237A (th) | อนุพันธ์เตตระไฮโดรไอโซควิโนลีนที่แทนที่ในฐานะเป็นสารดัดแปลงอัลโลสเตอริกด้านบวกของ d1 | |
| JP2008516898A5 (cg-RX-API-DMAC7.html) | ||
| HK1129593A1 (en) | Use of kcnq-opener for the preparation of a pharmaceutical composition for treating schizophrenia |